DEVELOPMENT OF LEAD AGENTS FOR ALS TREATMENT IN PRECLINICAL MODEL SYSTEMS BASED ON DIFFERENTIAL GENE EXPRESSION OF IGF-II
$1,082,703FY2008Department of the ArmyDOD
The Mclean Hospital Corporation
Investigators
View source on USAspending →DEVELOPMENT OF LEAD AGENTS FOR ALS TREATMENT IN PRECLINICAL MODEL SYSTEMS BASED ON DIFFERENTIAL GENE EXPRESSION OF IGF-II · GrantIndex